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Background: Renal cell carcinoma (RCC) may involve both kidneys. When bilateral nephrectomy is necessary renal
replacement therapy is mandatory. Treating such patients with sequential therapy based on cytokines,
antiangiogenic factors and mammalian target of rapamycin (mTOR) inhibitors is challenging.
Case presentation: The first case, a 50-year-old Caucasian female, underwent a radical right nephrectomy for RCC.
Twelve years later she underwent a radical left nephrectomy along with total hysterectomy including bilateral
salpingo-oophorectomy for RCC involving the right kidney and ovary. Hemodialysis was necessary because of
bilateral nephrectomy. She relapsed with pulmonary metastases and enlarged mediastinal lymph nodes and
received cytokine based therapy along with bevacizumab. Therapy was discontinued despite the partial response
because of hemorrhagic gastritis. Therapy was switched to an antiangiogenic factor but the patient manifested a
parietal brain hematoma and stopped therapy. Subsequently disease relapsed with malignant pleural effusion and
pulmonary nodules and a mammalian target of rapamycin inhibitor was administered which was withdrawn only at
patient’s deteriorating performance status. The patient died of the disease 13 years after the initial diagnosis of RCC.
The second case, a 51-year-old, Caucasian male, underwent a radical right nephrectomy for a chromophobe RCC.
Six months later he underwent a radical left nephrectomy for RCC that proved to be a clear cell RCC. Due to
bilateral nephrectomy hemodialysis was obligatory. Following disease recurrence at the anatomical bed of the right
kidney therapy with antiangiogenic factor was administered which led to disease regression. However the patient
experienced a left temporal-occipital brain hematoma. A radical excision of the recurrence which histologically
proved to be a chromophobe RCC was not achieved and the patient received mTOR inhibitor which led to disease
complete response. Nine years after the initial diagnosis of RCC he is disease free and leads an active life.
Conclusion: Patients with RCC are in significant risk to manifest bilateral disease. Renal insufficiency requiring
hemodialysis poses therapeutic challenges. Clinicians must be aware of the antiangiogenic factors’ adverse effects,
especially bleeding, that may manifest in higher frequency and more severe in this setting.
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Renal cell carcinoma (RCC) accounts for 2–3% of all
malignant tumors in adults and in Europe represents
the third most prevalent urologic malignancy [1].
Metastatic RCC (mRCC) is an aggressive tumor that
if left untreated confers a 5 year survival of 0–18%
[2]. At the time of diagnosis, one third of the patient* Correspondence: syriosi@yahoo.gr
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and one third of patients undergoing cytoreductive
nephrectomy will experience relapse and develop
metastasis [3].
The main histological subtypes of RCC are clear cell
(75–85% of tumors), papillary, chromophobe, oncocytic
and collecting duct carcinomas, which are associated
with specific cytogenetic and molecular abnormalities
[4]. Clear cell RCC typically carries the 3p deletion and
is associated with von Hippel-Lindau disease [5]. Al-
though most RCCs are sporadic, several syndromestd. This is an Open Access article distributed under the terms of the Creative
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RCC’s either synchronous or metachronous are associ-
ated with a hereditary predisposition [6,7].
Nephrectomy remains the cornerstone of treatment. It
is a prerequisite when the intention is to offer a radical
cure to the patient and is usually performed even in the
setting of mRCC, except for poor prognosis patients
according to MSKCC criteria [8]. In recent years nephron-
sparing surgery has largely substituted nephrectomy for
small renal tumors and is indicated in case of bilateral tu-
mors whenever feasible [9].
The standard therapy for mRCC beyond cytoreductive
surgery is currently based on tyrosine kinase inhi-
bitors (TKI’s) and mammalian target of rapamycin
(mTOR) inhibitors which prolong overall survival to
24 months [10].
Patients with mRCC who have severe renal insuffi-
ciency at diagnosis and those under hemodialysis follow-
ing bilateral nephrectomy pertain to a specific group
that poses therapeutic challenges to medical oncologists.
Since urinary excretion is a major elimination pathway
for many antineoplastic drugs, renal impairment may
alter the excretion rate of chemotherapeutic agents. Fur-
thermore, in patients undergoing hemodialysis the drug
clearance by dialysis must be taken into account for
appropriate timing and dosage of chemotherapy. None-
theless, there are no established guidelines about the
management of chemotherapy administration and tox-
icity in patients undergoing dialysis [11,12]; albeit both
TKI’s and mTOR inhibitors have mainly hepatic metab-
olism and only a minor renal excretion [13-16].
In this case report and short literature review we
present 2 patients with bilateral RCC who underwent
bilateral nephrectomy and received therapy based on
cytokines, antiangiogenic factors, inhibitors of tyrosine
kinases receptors and inhibitors of the mammalian tar-
get of rapamycin while on hemodialysis.
Case presentation
The first case, a 50-year-old Caucasian female with a
medical history of insulin-dependent diabetes mellitus
and hypertension underwent in 1996 a radical left
nephrectomy for RCC grade 3, stage T3N0, clear cell
carcinoma which was revealed on routine abdominal
ultrasound (US) exam. Because of persistent emesis in
July 2008 she underwent a gastroscopy and an abdom-
inal computed tomography scan (CT) which was signifi-
cant for a large mass in the right kidney consistent with
renal cell carcinoma and for a second one in her right
ovary. Given the large volume of the tumor that invaded
the renal vein a nephron-sparing procedure was not
feasible. A radical nephrectomy along with total
abdominal hysterectomy (TAH) with bilateral salpino-
oophorectomy was performed. Pathology assessment ofthe nephrectomy specimen revealed a Fuhrman grade 3,
clear cell renal carcinoma that invaded the Gerota fascia,
the renal vein and 1 out of 8 para-aortic lymph nodes,
staged as T4N1. The TAH specimen revealed an invaded
by the same renal clear cell carcinoma right ovary. Be-
cause of a high preoperative serum creatinine and urea
the patient required renal replacement therapy which
was continued postoperatively 3 times weekly. On
February 2009, a chest CT scan performed on a regular
follow-up basis revealed multiple pulmonary nodules
and enlarged aorta-pulmonary lymph nodes. A cytokine
based therapy including Interferon alfa-2b 6 MU admin-
istered three times per week subcutaneously, along with
Bevacizumab 200 mg intravenously weekly, was started.
A partial response of the disease which consisted of
disappearance of pulmonary nodules and stability of the
mediastinal lymph nodes was observed two months
after the initiation of the regimen. Nevertheless, on
September 2009 the patient complained of hematemesis
and melena. A hemorrhagic gastritis on the grounds of
angiodysplasia was diagnosed at gastroscopy which
forced the discontinuation of therapy. The hemorrha-
gic gastritis due to angiodysplasia was attributed to
Bevacizumab and also to the administration of heparin
during dialysis. Upon her recovery from gastric
hemorrhage she resumed therapy based on Sunitinib at
50 mg/day for 4 weeks with a 2-week washout phase.
However, 3 weeks after Sunitinib administration the pa-
tient experienced left hemiparesis along with expressive
aphasia, symptoms caused by a right parietal hematoma
as shown on brain CT scan. The brain magnetic reson-
ance imaging (MRI) performed subsequently verified the
findings of the CT scan and therapy based on
antiangiogenic factors was permanently withheld. Only
after the disease relapsed with malignant pleural effusion
and pulmonary nodules on December 2009 did the
patient resume therapy based on a second generation
mTOR inhibitor. The patient was on Everolimus 10 mg/
day per os until March 2010 when therapy was discon-
tinued because of the patient’s deteriorating performance
status. She died of the renal carcinoma on May 2010,
13 years after the initial diagnosis of RCC.
The second case, a 51-year-old Caucasian male, a heavy
smoker, complained of abdominal discomfort and an ab-
dominal ultrasound (US) exam performed in June 2004
was significant for a mass in the right kidney, consistent
with RCC. He underwent a radical right nephrectomy that
was histologically proved to be a chromophobe RCC of
nuclear grade Fuhrman 4, stage T1N0. Following regular
follow-up with abdominal US in December 2004, a solid
mass in his left kidney was revealed, which was again
consistent with RCC. He underwent a radical left nephrec-
tomy and the lesion histologically proved to be a clear cell
RCC, of nuclear grade Fuhrman 3, stage T1N0. The
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a three times weekly course of hemodialysis. In December
2009 after a regular basis follow-up with abdominal CT
scan, an asymptomatic local disease recurrence at the ana-
tomical bed of the right kidney consisting of a solid mass
of 34 mm diameter with central calcification, displacing
the inferior vena cava and psoas muscle was diagnosed.
Sunitinib at 50 mg/day for 4 weeks with a 2-week washout
phase was then administered leading to partial disease re-
sponse. A radical excision of the recurrence was attempted
in January 2010, however the surgical margins were
macroscopically invaded by RCC. Interestingly, the lesion
was histologically proved to be a recurrence of the primary
chromophobe RCC. Two weeks after the resection the
patient manifested a subacute left temporal-occipital
hematoma in brain CT scan which was attributed mainly
to a hemostasis disorder induced by the dialysis proce-
dures. Due to postoperative residual disease the patient
was treated with a second generation mTOR inhibitor,
Everolimus 10 mg/day per os which led to complete re-
sponse of the disease, without major toxicity. Nine years
after the initial diagnosis of RCC he is disease free and
leads an active life.
Discussion
The incidence of bilateral RCC either synchronous or
metachronous has been reported to be 2–13% [17]. Pa-
tients with RCC are in high risk to manifest a second RCC
either in the affected kidney in case of partial nephrectomy
or in the contralateral one [7]. In Rabbani’s et al. study
[18] the incidence of metachronous contralateral RCC was
stable on long-term follow-up; however it was strikingly
high during the first 5 years of follow-up.
Although most RCCs are sporadic, several syndromes
associated with bilateral RCC have been described [6,7].
Hereditary renal cancers are usually multiple, bilateral and
often occur at a young age. In support of this epidemio-
logic observation, Klatte et al. [19] reported that among
patients with bilateral RCC, familial predisposition was
found in 14.3% of them. Additionally, the von Hippel-
Lindau (VHL) disease was observed in 4.3% of cases. In
terms of pathology, the clear cell RCC typically carries the
3p deletion and is associated with VHL disease [5].
The first patient of the study was diagnosed in 1996
with a clear cell RCC of the left kidney, grade 3, stage
T3N0M0. The patient suffered from diabetes mellitus
which has not been proved a risk factor for RCC; how-
ever, diabetes induced hypertension is an established risk
factor for developing RCC [20]. In 2008 she developed a
second clear cell RCC at the contralateral kidney. The
fact that metachronous RCC appeared 12 years after the
primary diagnosis is consistent with the suggestion of
Rabbani et al. [18] that surveillance of the contralateral
kidney should remain rigorous on extended follow-up.Interestingly, the second RCC patient of the study, a
young Caucasian heavy smoker male, recurred in the first
6 months from the diagnosis of the primary lesion fulfill-
ing the temporal criteria for synchronous cancer; however
the contralateral lesion was of a different histology. The
histological discrepancy between the two synchronous
tumors is an extremely rare phenomenon which led us to
regard the second lesion as a second primary.
Patients with bilateral or multifocal RCC are in high
risk to develop renal insufficiency. Over the past decade
an increasing number of authors advocated the nephron
sparing surgery to overcome the risk of end stage renal
disease and the need for renal replacement therapy
[9,21]. Currently, partial nephrectomy is recommended
for small lesions <7 cm without compromising overall
survival. It is also the treatment of choice in case of bi-
lateral RCC, non-functional contralateral kidney, solitary
kidney; however, surgical feasibility is a major criterion
for partial nephrectomy [9].
In the cases where nephron sparing technique is not
technically feasible, radical open or laparoscopic neph-
rectomy is required. In such circumstances patients
undergo renal replacement therapy, either hemodialysis
or peritoneal dialysis; however a possible alternative in
disease free patients is kidney transplantation [22].
In both patients of the present study dialysis was
mandatory due to bilateral nephrectomy. Treating pa-
tients under renal replacement therapy is challenging
and scant literature dealing with this issue is currently
available. In patients who undergo dialysis the excretion
of drugs that normally have a renal excretion follow the
dialysis’ clearance rate. It is therefore important to evalu-
ate the fraction of active substance removed by dialysis
in order to plan therapy and avoid major toxicity. On
the other hand, for drugs that are not excreted by dialy-
sis administration can take place even shortly before the
dialysis. There are three indices to estimate the influence
of hemodialysis on drug pharmacokinetics, which in-
clude the dialysis clearance, the extraction ratio, and the
dialysis extraction factor coefficient [23]. Janus’s et al.
[11] study addresses the question on dosage adjustment
and timing of chemotherapy in hemodialyzed patients;
however, no information is provided about the newer
agents used in mRCC treatment.
The current medical armamentarium for metastatic
RCC includes cytokines (including interferon-α and
interleukine-2), antiangiogenic factors that inhibit
directly VEGF (Bevacizumab), others that target VEGF
receptors and tyrosine kinases receptors (sorafenib,
sunitinib, pazopanib, axitinib) and factors that inhibit
the mammalian target of rapamycin (temsirolimus and
everolimus) [24]. With the development of these agents,
the progression-free survival (PFS) has practically dou-
bled and up to 30% of patients achieve partial remission
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clusively with targeted agents the median overall survival
(OS) was 24 months (95% CI 20.0, 27.0) and the 5-year
OS rate was 24.6% (95% CI 18.7, 30.8%). Interestingly,
patients of all prognostic groups participated in this
study [10].
Nonetheless, no patients undergoing hemodialysis
were included in these studies highlighting the scarcity
of data in this clinically relevant minority of patients.
Interferon alfa-2b has a primarily renal metabolism.
Evidence based on case reports suggests that RCC pa-
tients undergoing dialysis receive low dose Interferon
alfa-2b [26] or modify the interval between injections
[27]. The first patient of the study received Interferon
alfa-2b 6 MU administered subcutaneously three times
per week along with Bevacizumab 200 mg intravenously
weekly, which was discontinued due to hemorrhagic gas-
tritis partly attributed to Bevacizumab.
Bevacizumab is a monoclonal antibody that inhibits
the vascular endothelial growth factor (VEGF). There is
only one study [28] evaluating the pharmacokinetics of
bevacizumab in a mRCC patient requiring hemodialysis.
In this study Bevacizumab was instituted at a dose of
5 mg/kg every 2 weeks and its pharmacokinetic parame-
ters were similar to the reference values of patients with
normal renal function. Moreover, bevacizumab is not di-
alyzable and it may therefore be administered even be-
fore dialysis. Further information can be retrieved by
studies on patients with metastatic colorectal cancer
under dialysis, receiving FOLOFOX/FOLFIRI along with
bevacizumab [29,30] with no dose reduction or toxicity
from the antibody described. The first patient of the
study manifested significant hemorrhagic gastritis while
she was on Bevacizumab, so treatment was withheld.
Given the fact that in gastroscopy extensive gastric
angiodysplasias were found, the gastrointestinal hemor-
rhage manifesting as hematemesis was co-attributed to
Bevacizumab, taking also into account the increased risk
for gastric angiodysplasia in end-stage renal disease
(ESRD) patients undergoing dialysis.
Sunitinib inhibits the receptor tyrosine kinases (RTKs)
VEGF, VEGFR2, PDGFR, FLT-3 and c-KIT and seems to
be well tolerated in patients on hemodialysis. In a pub-
lished case report of 2 patients with ESRD receiving re-
peated doses of sunitinib (daily for four weeks on, two
weeks off ) for renal cell cancer, the pharmacokinetics of
sunitinib were similar to those of patients with normal
renal function [13]. Another report included 10 patients
undergoing dialysis with doses starting from 25 to
50 mg daily for 4 out of 6 weeks. Treatment efficacy was
comparable to that reported in patients with normal
renal function while dose reduction for toxicity was re-
quired in 8, but only 1 patient required treatment dis-
continuation [31]. A phase I study indicated that thedose of sorafenib, an inhibitor of multiple RTKs including
VEGF-2, FLT-3, PDGF, FGFR-1 and Raf, should be re-
duced to 200 mg twice daily for patients on hemodialysis
[15]. Masini et al. [32] concur that sunitinib and sorafenib
treatment are not contraindicated in patients with mRCC
undergoing dialysis since the outcome is similar to that
observed in patients with normal renal function. The pa-
tients of our study received Sunitinib at 50 mg/day for
4 weeks with a 2-week washout phase but both experi-
enced major bleeding events, such as brain hematomas.
Treatment was withdrawn in both cases and the cause
of hematomas seemed to be multifactorial. Both pa-
tients received therapy the day after dialysis and their
serum urea was always above normal values. Moreover,
in routine hemodialysis anticoagulation measures are
taken consisting of a standard dose of heparin given as
a bolus at the start of the dialysis treatment with a mid-
treatment dose to maintain suitable anticoagulation.
The administration of an antiangiogenetic factor in pa-
tients who receive routine anticoagulation during dialysis,
could both contribute to a disequilibrium of hemostasis
that ultimately could manifest as a multicausal, clinically
significant hemorrhage.
Temsirolimus is a parenterally administered inhibitor of
the mammalian target of rapamycin (mTOR) kinase.
Temsirolimus undergoes hepatic metabolism and is
mainly excreted via the feces. Due to the small amount of
renal excretion dose adjustment is not needed in the set-
ting hemodialysis [14]. Everolimus is an orally adminis-
tered mTOR inhibitor. It is extensively metabolized in the
liver via CYP3A4 and is excreted by 80% in feces and only
by 5% in the urine. Recently, Tiery-Vuillemin et al. [16]
evaluated Everolimus pharmacokinetic parameters in two
patients suggesting that there is no influence of
hemodialysis on Everolimus blood concentrations. How-
ever, in the first case of their study a dose reduction from
10 mg/day to 5 mg/day was required due to grade 3 asthe-
nia, while in the second patient no dose escalation from
5 mg/day was achieved due to grade 3 dyslipidemia. The
second patient of our study received Everolimus 10 mg/
day per os which led to complete response of the disease,
without any major toxicity.
Since many new targeted drugs such as pazopanib and
axitinib are currently at clinicians’ disposal and others in-
cluding Etaracizumab, Vorinostat, XL880 and Infliximab
are under study, it is advisable that current literature be
supplemented with studies addressing administration pro-
tocols and toxicity surveillance of the newer agents in
RCC patients with end-stage renal disease in order to fur-
ther optimize our current treatment strategy.
Conclusion
In patients diagnosed with RCC, especially those with
young age at diagnosis, the risk to develop a secondary
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Nephron sparing surgery is the treatment of choice if
technically feasible. Patients undergoing hemodialysis be-
cause of bilateral nephrectomy pertain to a group that poses
therapeutic challenges to clinicians. Since there are no
established guidelines on management of therapy adminis-
tration and toxicity in mRCC patients undergoing dialysis,
therapy should be given with caution and increased vigi-
lance for adverse effects. Medical oncologists must be aware
of the higher incidence of bleeding disorders in patients
undergoing hemodialysis. More studies on mRCC patients
treated with agents targeting molecular pathways under
hemodialysis are therefore needed.
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